N-Ethylpentylone
N-Ethylpentylone is a substituted cathinone and stimulant drug which was developed in the 1960s.
It has been reported as a novel designer drug in several countries including South Africa, New Zealand, the United States, and Australia.
In 2018, N-ethylpentylone was the most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures.
A doctor, David Caldicott, has said N-ethylpentylone "can cause circulation problems, lethal heart palpitations and hallucinations". It has been linked to a number of overdose deaths and mass-casualty incidents, and has increasingly been mis-sold as MDMA.
N-Ethylpentylone is primarily a mixed norepinephrine reuptake inhibitor and dopamine reuptake inhibitor. It binds to transporters with IC50 values of 37 nM, 105 nM and 383 nM.Legality
In the United States, N-ethylpentylone is a Schedule I controlled substance.
